BRPI0918988A2 - métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina. - Google Patents
métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina.Info
- Publication number
- BRPI0918988A2 BRPI0918988A2 BRPI0918988A BRPI0918988A BRPI0918988A2 BR PI0918988 A2 BRPI0918988 A2 BR PI0918988A2 BR PI0918988 A BRPI0918988 A BR PI0918988A BR PI0918988 A BRPI0918988 A BR PI0918988A BR PI0918988 A2 BRPI0918988 A2 BR PI0918988A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- immunogen
- ampoule
- preserving
- excipient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0817526A GB0817526D0 (en) | 2008-09-24 | 2008-09-24 | Method for preserving polypeptides |
| GB0817525A GB0817525D0 (en) | 2008-09-24 | 2008-09-24 | Method for preserving antibodies |
| GB0817524A GB0817524D0 (en) | 2008-09-24 | 2008-09-24 | Method for preserving vaccine immunogens |
| GB0817527A GB0817527D0 (en) | 2008-09-24 | 2008-09-24 | Method for preserving enzymes |
| PCT/GB2009/002283 WO2010035001A1 (en) | 2008-09-24 | 2009-09-24 | Method for preserving polypeptides using a sugar and polyethyleneimine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0918988A2 true BRPI0918988A2 (pt) | 2015-12-01 |
Family
ID=41335570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0918988A BRPI0918988A2 (pt) | 2008-09-24 | 2009-09-24 | métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110236412A1 (pt) |
| EP (1) | EP2364319A1 (pt) |
| JP (1) | JP2012503637A (pt) |
| KR (1) | KR20110079670A (pt) |
| CN (1) | CN102164943A (pt) |
| AU (1) | AU2009295623A1 (pt) |
| BR (1) | BRPI0918988A2 (pt) |
| CA (1) | CA2737407A1 (pt) |
| GB (1) | GB2479069B (pt) |
| IL (1) | IL211776A0 (pt) |
| MX (1) | MX2011003074A (pt) |
| WO (1) | WO2010035001A1 (pt) |
| ZA (1) | ZA201101393B (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011001624A (es) | 2008-08-21 | 2011-03-28 | Octapharma Ag | Factor viii y ix humano producido en forma recombinante. |
| WO2010026186A1 (en) * | 2008-09-03 | 2010-03-11 | Octapharma Ag | New protecting compositions for recombinantly produced factor viii |
| US20110212127A1 (en) * | 2008-09-24 | 2011-09-01 | Stabilitech Ltd. | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
| JP5804453B2 (ja) * | 2009-05-14 | 2015-11-04 | 国立大学法人 東京大学 | 結晶性ポリオール微粒子及びその調製方法 |
| CA2795050C (en) | 2010-03-31 | 2018-05-22 | Stabilitech Ltd. | Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| WO2011121301A1 (en) | 2010-03-31 | 2011-10-06 | Stabilitech Ltd | Excipients for stabilising viral particles, polypeptides or biological material |
| ES2757591T3 (es) | 2010-03-31 | 2020-04-29 | Stabilitech Biopharma Ltd | Estabilización de partículas virales |
| CA2796729C (en) | 2010-04-20 | 2020-06-23 | Octapharma Ag | Melezitose for stabilizing human blood plasma proteins |
| PL3552619T3 (pl) | 2010-07-09 | 2025-12-01 | Bioverativ Therapeutics Inc. | Polipeptydy czynnika ix i sposoby ich zastosowania |
| WO2012018628A1 (en) | 2010-07-26 | 2012-02-09 | Board Of Regents, The University Of Texas System | Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine |
| EP2598167B1 (en) * | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| CA2861402C (en) | 2012-01-30 | 2021-10-12 | Guy Casy | Stabilized aqueous antibody compositions |
| HK1213521A1 (zh) | 2012-09-25 | 2016-07-08 | Bioverativ Therapeutics Inc. | Fix多肽的應用 |
| US9974850B2 (en) | 2013-01-25 | 2018-05-22 | Board Of Regents, The University Of Texas System | Immunogenic compositions and uses thereof |
| WO2014144549A1 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor ix polypeptide formulations |
| US10128481B2 (en) * | 2014-02-18 | 2018-11-13 | GM Global Technology Operations LLC | Lithium-based battery separator and method for making the same |
| AU2015236340B2 (en) | 2014-03-24 | 2020-02-06 | Bioverativ Therapeutics Inc. | Lyophilized factor IX formulations |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| CN110100162B (zh) * | 2016-12-22 | 2022-08-30 | 文塔纳医疗系统公司 | 用于样本处理的系统和方法 |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| CN109991218A (zh) * | 2019-03-29 | 2019-07-09 | 迪瑞医疗科技股份有限公司 | 一种凝固酶检测试纸的制备方法 |
| CN109991221A (zh) * | 2019-03-29 | 2019-07-09 | 迪瑞医疗科技股份有限公司 | 一种脯氨酸氨基肽酶检测试纸的制备方法 |
| EP4151230A4 (en) * | 2020-05-15 | 2023-11-08 | JNC Corporation | ANTIVIRAL AGENT |
| CN113512598B (zh) * | 2020-12-07 | 2024-03-22 | 上海仁度生物科技股份有限公司 | 百日咳杆菌的实时荧光核酸恒温扩增检测试剂盒及其专用引物和探针 |
| NL2027785B1 (en) * | 2021-03-19 | 2022-09-29 | Original G B V | Method for the in vitro diagnosis of infection |
| CN114392237B (zh) * | 2021-12-28 | 2024-02-02 | 上海允英生物医药科技有限公司 | 一种冻干病毒制剂及其制备方法 |
| CN114762731B (zh) * | 2022-05-16 | 2024-08-23 | 常州大学 | 一种延长基因药物在温和条件下储存时间的方法 |
| WO2024100130A1 (en) * | 2022-11-11 | 2024-05-16 | Merck Patent Gmbh | Thermostable vaccin formulations and process for preparing the same |
| CN116286726B (zh) * | 2023-03-17 | 2026-04-24 | 翌圣生物科技(上海)股份有限公司 | 一种低偏好性dna片段化的酶组合物及其反应液 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4950596A (en) * | 1985-03-04 | 1990-08-21 | The Dow Chemical Company | Stabilization of intracellular enzymes |
| JPS6238173A (ja) * | 1985-08-13 | 1987-02-19 | 三菱レイヨン株式会社 | 抗血液凝固剤 |
| US5169758A (en) * | 1986-05-02 | 1992-12-08 | Boehringer Mannheim Gmbh | Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it |
| NZ221306A (en) * | 1986-08-15 | 1990-02-26 | Commw Scient Ind Res Org | 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof |
| GB8826429D0 (en) * | 1988-11-11 | 1988-12-14 | Univ Leeds Ind Service Ltd | Enzyme stabilisation systems |
| DE69032102T2 (de) * | 1989-08-15 | 1998-06-25 | Massachusetts Inst Technology | Stabilisierte impfstoffzusammensetzungen |
| ES2158886T3 (es) * | 1992-12-01 | 2001-09-16 | Tetsuro Higashikawa | Jeringuilla. |
| CN1286725A (zh) * | 1997-11-26 | 2001-03-07 | 环球保藏技术股份有限公司 | 敏感性生物样品的玻化保质法 |
| EP1032647B1 (en) * | 1997-11-26 | 2006-03-29 | Universal Preservation Technologies, Inc. | Preservation of sensitive biological samples by vitrification |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US20060247167A1 (en) * | 2003-09-01 | 2006-11-02 | Novo Nordisk A/S | Stable formulations of peptides |
| JP2007527431A (ja) * | 2004-03-03 | 2007-09-27 | ルバンス セラピュティックス | 局所的診断及び治療用の輸送のための組成物及び方法 |
| KR101341359B1 (ko) * | 2004-10-01 | 2013-12-13 | 램스코르 인코포레이티드 | 편리하게 이식가능한 서방형 약물 조성물 |
| GB0502661D0 (en) | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| GB0705245D0 (en) * | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| US20090123436A1 (en) * | 2007-11-08 | 2009-05-14 | Surmodics, Inc. | Cryopreservative compositions and methods |
| US20110212127A1 (en) * | 2008-09-24 | 2011-09-01 | Stabilitech Ltd. | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
-
2009
- 2009-09-24 MX MX2011003074A patent/MX2011003074A/es not_active Application Discontinuation
- 2009-09-24 WO PCT/GB2009/002283 patent/WO2010035001A1/en not_active Ceased
- 2009-09-24 CA CA2737407A patent/CA2737407A1/en not_active Abandoned
- 2009-09-24 BR BRPI0918988A patent/BRPI0918988A2/pt not_active IP Right Cessation
- 2009-09-24 EP EP09785161A patent/EP2364319A1/en not_active Withdrawn
- 2009-09-24 US US13/120,539 patent/US20110236412A1/en not_active Abandoned
- 2009-09-24 JP JP2011528415A patent/JP2012503637A/ja active Pending
- 2009-09-24 GB GB1106784.0A patent/GB2479069B/en not_active Expired - Fee Related
- 2009-09-24 CN CN2009801373891A patent/CN102164943A/zh active Pending
- 2009-09-24 AU AU2009295623A patent/AU2009295623A1/en not_active Abandoned
- 2009-09-24 KR KR1020117009312A patent/KR20110079670A/ko not_active Withdrawn
-
2011
- 2011-02-22 ZA ZA2011/01393A patent/ZA201101393B/en unknown
- 2011-03-17 IL IL211776A patent/IL211776A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012503637A (ja) | 2012-02-09 |
| US20110236412A1 (en) | 2011-09-29 |
| GB201106784D0 (en) | 2011-06-01 |
| KR20110079670A (ko) | 2011-07-07 |
| WO2010035001A1 (en) | 2010-04-01 |
| EP2364319A1 (en) | 2011-09-14 |
| GB2479069A8 (en) | 2011-12-21 |
| CA2737407A1 (en) | 2010-04-01 |
| AU2009295623A1 (en) | 2010-04-01 |
| IL211776A0 (en) | 2011-06-30 |
| MX2011003074A (es) | 2011-04-19 |
| GB2479069A (en) | 2011-09-28 |
| GB2479069B (en) | 2012-07-25 |
| ZA201101393B (en) | 2013-05-29 |
| CN102164943A (zh) | 2011-08-24 |
| HK1159119A1 (en) | 2012-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0918988A2 (pt) | métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina. | |
| IL268756B (en) | Piperazine-2,5-dione derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments | |
| MX2023003875A (es) | Formulacion de una vacuna peptidica. | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| PL3804714T3 (pl) | Farmaceutyczna kombinacja i kompozycja oraz preparat złożony zawierające aktywator glukokinazy i lek hipoglikemizujący z grupy biguanidów, a także sposób ich wytwarzania i ich zastosowanie | |
| CL2014003171A1 (es) | Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica. | |
| CY1119435T1 (el) | Σκευασμα για αντισωμα εναντι- αλφα4βητα7 | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| BR112013011949A2 (pt) | "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis" | |
| IT1399104B1 (it) | Capsula contenente una dose di una sostanza per la preparazione di una bevanda, e metodo per preparazione di una bevanda utilizzante tale capsula. | |
| BR112015015758A2 (pt) | dispersão sólida, formulação sólida, método de preparo de uma dispersão sólida, preparação farmacêutica e uso de uma dispersão sólida | |
| WO2011161226A3 (en) | Novel antibody formulation | |
| WO2012149365A3 (en) | Antibodies selective for pathological tau dimers and oligomers and their uses in treatment, diagnosis, monitoring of tauopathies | |
| BR112016013832A2 (pt) | Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico | |
| EP4338803A3 (en) | Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes | |
| BR112016027595A8 (pt) | produtos de peptídeos, composição farmacêutica compreendendo um produto de peptídeo, uso de um produto de peptídeo e método para produzir um produto de peptídeo | |
| BR112015031979A2 (pt) | letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir. | |
| BR112016012489A2 (pt) | cápsula, método de preparação de uma cápsula contendo flavonoides totais de desmodium styracifolium, e uso da cápsula | |
| EA201700019A1 (ru) | Высокочистый оритаванцин и способ его получения | |
| CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. | |
| JOP20200053A1 (ar) | تركيبات كوبانليسيب | |
| IL280376A (en) | The history of boronic acid, its preparation and pharmaceutical preparations containing it | |
| DK3404033T3 (da) | C-glukosidderivat med kondenseret phenylring eller farmaceutisk acceptabelt salt deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende dette |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |